Posts
Safety considerations for cereblon-recruiting targeted protein degraders
Aclairo’s Ron Wange and the HESI Targeted Protein Degrader Safety Group recently published a review of key safety issues with
Rethinking Clinical Trials for Pregnant and Breastfeeding Patients
Pregnant and breastfeeding individuals have long been excluded from clinical drug development, leaving physicians and patients to make critical treatment
Advancing Treg Cell Therapy
Uyen Dinh, PhD and I were delighted to be asked to contribute to a special edition of Frontiers in Immunology
SOT 65th Annual Meeting
EPL and Aclairo Pharmaceutical Development Group, Inc. are looking forward to seeing everyone at the SOT 65th Annual Meeting in
FDA Gene Editing Guidance
FDA has issued a new gene editing guidance that gives additional information on expectations for use of next-generation sequencing. The
HESI Targeted Protein Degrader Safety Group
Aclairo’s Ron Wange and the HESI Targeted Protein Degrader Safety Group recently published a review of key safety issues with
ASGCT 2026
Jennifer Wheeler, Uyen Dinh, PhD, and Lauren Mihalcik, PhD, DABT will all be in Boston next week for ASGCT. This
News & Events
ASGCT
Meet us in Boston – May 11 – 15, 2026